GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (MEX:RARE) » Definitions » E10

Ultragenyx Pharmaceutical (MEX:RARE) E10 : MXN-131.55 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultragenyx Pharmaceutical E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted earnings per share data for the three months ended in Jun. 2024 was MXN-27.847. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN-131.55 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-09-25), Ultragenyx Pharmaceutical's current stock price is MXN751.98. Ultragenyx Pharmaceutical's E10 for the quarter that ended in Jun. 2024 was MXN-131.55. Ultragenyx Pharmaceutical's Shiller PE Ratio of today is .


Ultragenyx Pharmaceutical E10 Historical Data

The historical data trend for Ultragenyx Pharmaceutical's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical E10 Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -117.36 -107.56

Ultragenyx Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -128.38 -118.23 -107.56 -113.55 -131.55

Competitive Comparison of Ultragenyx Pharmaceutical's E10

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Shiller PE Ratio falls into.



Ultragenyx Pharmaceutical E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-27.847/132.5538*132.5538
=-27.847

Current CPI (Jun. 2024) = 132.5538.

Ultragenyx Pharmaceutical Quarterly Data

per share eps CPI Adj_EPS
201409 -6.713 100.428 -8.860
201412 -7.670 99.070 -10.262
201503 -9.604 99.621 -12.779
201506 -13.023 100.684 -17.145
201509 -17.405 100.392 -22.981
201512 -24.933 99.792 -33.118
201603 -23.239 100.470 -30.660
201606 -27.001 101.688 -35.197
201609 -31.710 101.861 -41.265
201612 -36.080 101.863 -46.951
201703 -30.691 102.862 -39.550
201706 -31.091 103.349 -39.877
201709 -33.937 104.136 -43.198
201712 -37.119 104.011 -47.305
201803 11.264 105.290 14.181
201806 -20.828 106.317 -25.968
201809 -32.547 106.507 -40.507
201812 -33.969 105.998 -42.479
201903 -35.304 107.251 -43.633
201906 -33.039 108.070 -40.524
201909 -38.694 108.329 -47.347
201912 -30.553 108.420 -37.354
202003 -48.068 108.902 -58.508
202006 9.464 108.767 11.534
202009 -24.963 109.815 -30.132
202012 -7.360 109.897 -8.877
202103 -41.495 111.754 -49.218
202106 -36.030 114.631 -41.663
202109 -22.207 115.734 -25.434
202112 -36.720 117.630 -41.379
202203 -43.605 121.301 -47.650
202206 -45.467 125.017 -48.208
202209 -70.402 125.227 -74.521
202212 -42.111 125.222 -44.577
202303 -41.998 127.348 -43.715
202306 -38.574 128.729 -39.720
202309 -38.844 129.860 -39.650
202312 -25.801 129.419 -26.426
202403 -33.690 131.776 -33.889
202406 -27.847 132.554 -27.847

Add all the adjusted EPS together and divide 10 will get our e10.


Ultragenyx Pharmaceutical  (MEX:RARE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ultragenyx Pharmaceutical E10 Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.